Loading...
Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stress‐Regulated Protein Translation
PTC299 is a novel small molecule that specifically blocks the production of protein from selected mRNAs that under certain conditions use noncanonical ribosomal translational pathways. Hypoxia, oncogenic transformation, and viral infections limit normal translation and turn on these noncanonical tra...
Na minha lista:
| Udgivet i: | Clin Pharmacol Drug Dev |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5066743/ https://ncbi.nlm.nih.gov/pubmed/27310330 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.240 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|